Paper Details

  1. Home
  2. Paper Details

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Author: AbidiMuneer H, BarlogieBart, DispenzieriAngela, DurieBrian G M, EpsteinJoshua, HoeringAntje, KahanicStephen P, OrlowskiRobert Z, RajkumarS Vincent, ReuFrederic, ReynoldsChristopher M, SextonRachael, ThakuriMohan

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examines the use of bortezomib in combination with lenalidomide and dexamethasone for treating patients with previously untreated multiple myeloma who are not candidates for immediate autologous stem-cell transplantation. The study investigates whether adding bortezomib can improve treatment outcomes.
Paper Details　
Original Abstract of the Article :
Lenalidomide plus dexamethasone is a reference treatment for patients with newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with lenalidomide and dexamethasone has shown significant efficacy in the setting of newly diagnosed myeloma. We aimed to study whether the addit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28017406

データ提供：米国国立医学図書館（NLM）

Bortezomib + Lenalidomide + Dexamethasone: A Powerful Trio for Myeloma?

This research explores the world of multiple myeloma (MM), a type of cancer affecting plasma cells in the bone marrow. The study investigates the efficacy of adding the proteasome inhibitor bortezomib to the standard treatment regimen of lenalidomide and dexamethasone for newly diagnosed MM patients who are not candidates for immediate autologous stem-cell transplant. This study is crucial for advancing treatment options for MM and improving patient outcomes.

A Promising Combination: Enhanced Efficacy in MM

The study, conducted by the Southwest Oncology Group (SWOG), revealed that adding bortezomib to lenalidomide and dexamethasone significantly improved progression-free survival and response rates in patients with newly diagnosed MM. This finding suggests that this combination therapy may offer a more effective treatment approach for MM.

Optimizing Myeloma Treatment: Tailoring Therapy for Individual Needs

This study highlights the importance of tailoring treatment regimens to individual patient characteristics and needs. It underscores the need for ongoing research and clinical trials to evaluate the effectiveness of different treatment combinations for MM.

Dr.Camel's Conclusion

This research, like a camel traversing a vast desert in search of a hidden oasis, explores new treatment options for multiple myeloma. The study highlights the potential benefits of combining bortezomib with lenalidomide and dexamethasone, offering hope for improved patient outcomes.

Date :
  1. Date Completed 2018-02-23
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

28017406

DOI: Digital Object Identifier

NIHMS839821

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.